#Canada #Vancouver #mental health #Numinus Wellness #Psychedelic Therapy

Corporate Update from Numinus Wellness

Numinus Wellness Inc., a pioneering company in the field of mental health care, has made significant changes to its leadership. Effective January 23, 2025, Michael Tan has been appointed as the new Chief Executive Officer (CEO) of the company, succeeding Payton Nyquvest, who will now serve as the Executive Chair. This transition marks a pivotal moment for Numinus as it aims to enhance its focus on innovative and traditional behavioral health treatments, particularly those that involve evidence-based psychedelic-assisted therapies.

Michael Tan has been with Numinus since 2019, initially joining as Chief Operating Officer. His extensive experience and leadership have been instrumental in various facets of the company's operations, including mergers and acquisitions, as well as organizational realignments. As CEO, Tan has affirmed his commitment to strengthening Numinus' clinical research and training programs for practitioners, aiming to seize emerging opportunities in the mental health care arena.

In his own words, Tan stated, "I am committed to leading Numinus forward and pursuing opportunities for growth where we can create meaningful impact." He articulates a clear vision for the company's future, focusing on advancing areas with the highest potential for positive outcomes in mental health care.

Meanwhile, Payton Nyquvest, now in the role of Executive Chair, will continue to lend his expertise to the company's strategic direction, investor relations, and partnership initiatives. Nyquvest has been recognized as a trailblazer in the psychedelic therapy space, and his mentorship is expected to guide Numinus through its next phase of growth. "As I transition from CEO to Executive Chair, I look forward to supporting the leadership team and contributing to the Company's ongoing priorities," he noted, highlighting his dedication to the company's mission.

Additionally, it was announced that Allen Morishita has resigned from his position on the Board of Directors. Morishita has been a part of Numinus since its inception, and the company expressed gratitude for his guidance and expertise during his tenure.

Numinus Wellness is at the forefront of a transformative approach in mental health care, focusing on the integration of psychedelic-assisted therapies into mainstream clinical practice. Their model emphasizes technology-driven clinic support, clinical trials, and comprehensive training for practitioners, with a goal of enabling holistic healing rather than merely managing symptoms of mental health issues such as anxiety, depression, trauma, and substance use disorders.

With these leadership changes, Numinus aims to accelerate its efforts and maintain a robust presence in the mental health sector. As Tan and Nyquvest collaborate, the company is poised to expand its innovative treatment approaches, ultimately contributing to a healthier society.

Check out more about Numinus Wellness and its mission at www.numinus.com or follow their journey on platforms like LinkedIn and Instagram.

For stakeholders and investors, the company advises careful review of forward-looking statements in their releases, cautioning about potential risks and uncertainties that could affect future outcomes. Numinus is committed to transparency and aims to keep all parties informed as it navigates this exciting new chapter.

In summary, the restructuring at the top management of Numinus Wellness represents a strategic move towards reinforcing its commitment to innovation and excellence in mental health care.